Cited by 252PI3K/AKT/mTOR signaling in cancerSignaling Pathways in DiseaseAutophagy in Disease and Therapy

The DOI matches its Crossref record; 231 of the 256 references it cites were found in a registry or an index.

Rapamycin: An anti-cancer immunosuppressant?

Law, Brian K.·2005·Critical Reviews in Oncology/Hematology

DOI 10.1016/j.critrevonc.2004.09.009

Open this paper in CoChat — free account

Abstract

Rapamycin and its derivatives are promising therapeutic agents with both immunosuppressant and anti-tumor properties. These rapamycin actions are mediated through the specific inhibition of the mTOR protein kinase. mTOR serves as part of an evolutionarily conserved signaling pathway that controls the cell cycle in response to changing nutrient levels. The mTOR signaling network contains a number of tumor suppressor genes including PTEN, LKB1, TSC1, and TSC2, and a number of proto-oncogenes including PI3K, Akt, and eIF4E, and mTOR signaling is constitutively activated in many tumor types. These observations point to mTOR as an ideal target for anti-cancer agents and suggest that rapamycin is such an agent. In fact, early preclinical and clinical studies indicate that rapamycin derivatives have efficacy as anti-tumor agents both alone, and when combined with other modes of therapy. Rapamycin appears to inhibit tumor growth by halting tumor cell proliferation, inducing tumor cell apoptosis, and suppressing tumor angiogenesis. Rapamycin immunosuppressant actions result from the inhibition of T and B cell proliferation through the same mechanisms that rapamycin blocks cancer cell proliferation. Therefore, one might think that rapamycin-induced immunosuppression would be detrimental to the use of rapamycin as an anti-cancer agent. To the contrary, rapamycin decreases the frequency of tumor formation that occurs in organ transplant experiments when combined with the widely used immunosuppressant cyclosporine compared with the tumor incidence observed when cyclosporine is used alone. The available evidence indicates that with respect to tumor growth, rapamycin anti-cancer activities are dominant over rapamycin immunosuppressant effects.

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2004.09.009

Cites

231 of 231 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Phosphatidylinositol 3-Kinase/Akt Pathway Regulates Tuberous Sclerosis Tumor Suppressor Complex by Phosphorylation of Tuberin
Dan, H. C., Sun, M., Yang, L., Feldman, R. I., Sui, X.-M., Ou, C. C., Nellist, M. D., Yeung, R. S. W., Halley, D. J. J., Nicosia, S. V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205838200 · Cited by 370
Retracted
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,072
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,208
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
Polyák, K., Lee, M.-H., Erdjument‐Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,055
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053

Show all 256 references

Research works printed but not linked: 1

Smith, 1990, Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells, New Biol, 2, 648

Sorted by citations

LKB1-Dependent Signaling Pathways
Alessi, D. R., Sakamoto, K., & Bayascas, J. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142702 · Cited by 805
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J. M., Tudor, C., Chuck, G., Caré, M. M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 609
A Review of the Microbial Production of Bioactive Natural Products and Biologics
Pham, J. V., Yilma, M. A., Feliz, A., Majid, M. T., Maffetone, N., Walker, J. R., Kim, E., Cho, H. J., Reynolds, J. M., Song, M., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01404 · Cited by 570
Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological Profiles of Drugs
Wang, X., Pan, C., Gong, J., Liu, X., & Li, H. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00690 · Cited by 300
Cancer in the Transplant RecipientPreprint
Chapman, J. R., Webster, A. C., & Wong, G. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015677 · Cited by 277
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T. L., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 299
Excessive Autophagy Contributes to Neuron Death in Cerebral Ischemia
Shi, R., Weng, J., Zhao, L., Li, X., Gao, T., & Kong, J. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00295.x · Cited by 267
Targeting the nucleolus for cancer intervention
Quin, J. E., Devlin, J. R., Cameron, D. P., Hannan, K. M., Pearson, R. B., & Hannan, R. D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.009 · Cited by 230
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
Zhou, L., Huang, Y., Li, J., & Wang, Z. (2009) · Medical Oncology · doi:10.1007/s12032-009-9201-4 · Cited by 225
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer
Campbell, S. B., Walker, R. G., Tai, S. S., Jiang, Q. L., & Russ, G. R. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04004.x · Cited by 221
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Gupta, S., Roy, A., & Dwarakanath, B. S. R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00068 · Cited by 225
Relating drug–protein interaction network with drug side effects
Mizutani, S., Pauwels, E., Stoven, V., Goto, S., & Yamanishi, Y. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts383 · Cited by 210
Exploiting a precise design of universal synthetic modular regulatory elements to unlock the microbial natural products in Streptomyces
Bai, C., Zhang, Y., Zhao, X., Hu, Y., Xiang, S., Miao, J., Lou, C., & Zhang, L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511027112 · Cited by 201
Hedgehog signalling in skin development and cancer
Athar, M., Tang, X., Lee, J. L., Kopelovich, L., & Kim, A. L. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00473.x · Cited by 201
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Zhang, Y.-J., Duan, Y.-W., & Zheng, X.-F. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 176
Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma
Robb, V. A., Karbowniczek, M., Klein–Szanto, A. J., & Henske, E. P. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.08.076 · Cited by 165
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
Ching, C. B., & Hansel, D. E. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.133 · Cited by 155
Unexpected applications of secondary metabolites
Vaishnav, P., & Demain, A. L. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.11.006 · Cited by 154
An anti-aging drug today: from senescence-promoting genes to anti-aging pill
Blagosklonny, M. V. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.01.004 · Cited by 150
DAMPs, ageing, and cancer: The ‘DAMP Hypothesis’
Huang, J., Xie, Y., Sun, X., Zeh, H. J., Kang, R., Lotze, M. T., & Tang, D. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.10.004 · Cited by 144
Validation of anti-aging drugs by treating age-related diseases
Blagosklonny, M. V. (2009) · Aging · doi:10.18632/aging.100034 · Cited by 142
Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab
Barnett, R., Barta, V. S., & Jhaveri, K. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1614298 · Cited by 136
The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling
van Veelen, W., Korsse, S. E., van de Laar, L., & Peppelenbosch, M. P. (2011) · Oncogene · doi:10.1038/onc.2010.630 · Cited by 134
FK506-Binding Proteins and Their Diverse Functions
Tong, M., & Jiang, Y. (2015) · Current Molecular Pharmacology · doi:10.2174/1874467208666150519113541 · Cited by 135
PRAS40 Deregulates Apoptosis in Malignant Melanoma
Madhunapantula, S. V., Sharma, A. K., & Robertson, G. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4234 · Cited by 124
Caloric restriction: Beneficial effects on brain aging and Alzheimer’s disease
Van Cauwenberghe, C., Vandendriessche, C., Libert, C., & Vandenbroucke, R. E. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9647-6 · Cited by 121
Activating secondary metabolism with stress and chemicals
Yoon, V., & Nodwell, J. R. (2013) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-013-1387-y · Cited by 116
Therapeutic targeting of the mTOR ‐signalling pathway in cancer: benefits and limitations
Moschetta, M., Reale, A., Marasco, C., Vacca, A., & Carratù, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12749 · Cited by 119
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 122
The LKB1 tumor suppressor kinase in human disease
Katajisto, P., Vallenius, T., Vaahtomeri, K., Ekman, N., Udd, L., Tiainen, M., & Mäkelä, T. P. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.003 · Cited by 113
PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
Lai, Y. L., Mau, B.-L., Cheng, W., Chen, H. M., Chiu, H., & Tzen, C. ‐. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9751-7 · Cited by 107
The Target of Rapamycin Signalling Pathway in Ageing and Lifespan Regulation
Bjedov, I., & Rallis, C. (2020) · Genes · doi:10.3390/genes11091043 · Cited by 108
Identification of pyrimidine derivatives as hSMG-1 inhibitors
Gopalsamy, A., Bennett, E. M., Shi, M., Zhang, W., Bard, J., & Yu, K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.107 · Cited by 104
Overview of the Indications and Contraindications for Liver TransplantationPreprint
Farkas, S. A., Hackl, C., & Schlitt, H. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015602 · Cited by 101
Ca2+ microdomains in smooth muscle
McCarron, J. G., Chalmers, S., Bradley, K. N., MacMillan, D., & Muir, T. C. (2006) · Cell Calcium · doi:10.1016/j.ceca.2006.08.010 · Cited by 98
Frontier of Epilepsy Research - mTOR signaling pathway
Cho, C. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.5.032 · Cited by 93
Combination Strategies to Improve Targeted Radionuclide Therapy
Chan, T. G., O’Neill, E., Habjan, C., & Cornelissen, B. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.248062 · Cited by 91
Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-β
Rahimi, R. A., Andrianifahanana, M., Wilkes, M. C., Edens, M., Kottom, T. J., Blenis, J., & Leof, E. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2146 · Cited by 91
Insulin and TOR signal in parallel through FOXO and S6K to promote epithelial wound healing
Kakanj, P., Moussian, B., Grönke, S., Bustos, V., Eming, S. A., Partridge, L., & Leptin, M. (2016) · Nature Communications · doi:10.1038/ncomms12972 · Cited by 87
Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment
Mockler, M. B., Conroy, M. J., & Lysaght, J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00107 · Cited by 89
Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems
Tavakol, S., Ashrafizadeh, M., Deng, S., Azarian, M., Abdoli, A., Motavaf, M., Poormoghadam, D., Khanbabaei, H., Afshar, E. G., Mandegary, A., et al. (2019) · Biomolecules · doi:10.3390/biom9100530 · Cited by 92
The two faces of miR-29
Ślusarz, A., & Pulakat, L. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000246 · Cited by 89
Liver transplantation in children with hepatocellular carcinoma Do Milan criteria apply to pediatric patients?
Ismail, H., Broniszczak, D., Kaliciński, P., Markiewicz‐Kijewska, M., Teisseyre, J., Stefanowicz, M., Szymczak, M., Dembowska-Baginska, B. M., Kluge, P., Perek, D., et al. (2009) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2009.01062.x · Cited by 85
From rapalogs to anti-aging formula
Blagosklonny, M. V. (2017) · Oncotarget · doi:10.18632/oncotarget.18033 · Cited by 83
From nature to the laboratory and into the clinic
Nicolaou, K. C., Chen, J. S., & Dalby, S. M. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.089 · Cited by 81
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization
Leung, W., Gay, J. W., Martin, U., Garrett, T. E., Horton, H. M., Certo, M. T., Blazar, B. R., Morgan, R. A., Gregory, P. D., Jarjour, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124430 · Cited by 81
Disruption of Mammalian Target of Rapamycin Complex 1 in Macrophages Decreases Chemokine Gene Expression and Atherosclerosis
Ai, D., Jiang, H., Westerterp, M., Murphy, A. J., Wang, M., Ganda, A., Abramowicz, S., Welch, C. L., Almazan, F., Zhu, Y., et al. (2014) · Circulation Research · doi:10.1161/circresaha.114.302313 · Cited by 78
FK506 binding proteins: Cellular regulators of intracellular Ca2+ signalling
MacMillan, D. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.029 · Cited by 73
mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
Zhou, Q., Deng, Z., Zhu, Y., Long, H., Zhang, S., & Zhao, J. (2009) · Medical Oncology · doi:10.1007/s12032-009-9365-y · Cited by 77
Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration
Nelson, J. S., Jia, W., Phung, T. L., & Mihm, M. C. (2011) · Lasers in Surgery and Medicine · doi:10.1002/lsm.21141 · Cited by 75
The TOR Signaling Pathway in Spatial and Temporal Control of Cell Size and Growth
Gonzalez, S., & Rallis, C. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00061 · Cited by 70
Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity
Hedayati, N., Safari, M. H., Milasi, Y. E., Kahkesh, S., Farahani, N., Khoshnazar, S. M., Dorostgou, Z., Alaei, E., Alimohammadi, M., Rahimzadeh, P., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02471-w · Cited by 75
Aging, Stem Cells, and Mammalian Target of Rapamycin: A Prospect of Pharmacologic Rejuvenation of Aging Stem Cells
Blagosklonny, M. V. (2008) · Rejuvenation Research · doi:10.1089/rej.2008.0722 · Cited by 66
Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway
Tsai, H.-H., Lai, H.-Y., Chen, Y.-C., Li, C., Huang, H., Liu, H., Tsai, Y.-S., & Wang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14640 · Cited by 65
The Emerging Roles of Autophagy in Human Diseases
Lei, Y., & Klionsky, D. J. (2021) · Biomedicines · doi:10.3390/biomedicines9111651 · Cited by 68
Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors
Lam, C. G., Bouffet, É., Tabori, U. Y., Mabbott, D., Taylor, M. D., & Bartels, U. K. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22298 · Cited by 61
Regulation of mTOR by Polycystin-1: is Polycystic Kidney Disease a Case of Futile Repair?
Weimbs, T. (2006) · Cell Cycle · doi:10.4161/cc.5.21.3408 · Cited by 58
Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation
Takahashi, H., Wang, Y., & Grainger, D. W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.019 · Cited by 58
Effect of temozolomide on the U-118 glioma cell line
do Carmo, A., Carvalheiro, H., Crespo, I., Nunes‐Correia, I., & Lopes, M. C. (2011) · Oncology Letters · doi:10.3892/ol.2011.406 · Cited by 56
Immune Regulation by Rapamycin: Moving Beyond T Cells
Janes, M. R., & Fruman, D. A. (2009) · Science Signaling · doi:10.1126/scisignal.267pe25 · Cited by 58
Effect of sirolimus on coagulopathy of slow‐flow vascular malformations
Mack, J. M., Verkamp, B., Richter, G. T., Nicholas, R. W., Stewart, K., & Crary, S. E. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27896 · Cited by 55
Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro
Zhang, J., Liu, J., Lu, M.-Q., Cai, C.-J., Yang, Y., Li, H., Xu, C., & Chen, G. (2007) · Transplant Immunology · doi:10.1016/j.trim.2006.12.003 · Cited by 53
Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: Molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels
Tan, W., Jia, W., Sun, V. Z., Mihm, M. C., & Nelson, J. S. (2012) · Lasers in Surgery and Medicine · doi:10.1002/lsm.22101 · Cited by 53
Use of Everolimus as a Rescue Immunosuppressive Therapy in Liver Transplant Patients With Neoplasms
Gómez‐Camarero, J., Salcedo, M., Rincón, D., Iacono, O. L., Ripoll, C., Hernando, A., Sanz, C., Clemente, G., & Bañares, R. (2007) · Transplantation · doi:10.1097/01.tp.0000280549.93403.dd · Cited by 51
Molecular and therapeutic insights of rapamycin: a multi-faceted drug from Streptomyces hygroscopicus
Ganesh, S. K., & Devi, C. S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08283-x · Cited by 56
The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals
Tan, H. K., Moad, A. I. H., & Tan, M. L. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.16.6463 · Cited by 51
Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
Mazor, R., King, E. M., Onda, M., Çuburu, N., Addissie, S., Crown, D., Liu, X., Kishimoto, T., & Pastan, I. H. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717063115 · Cited by 49
Immunosuppressants in cancer prevention and therapy
Blagosklonny, M. V. (2013) · OncoImmunology · doi:10.4161/onci.26961 · Cited by 48
Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial
Ahmadi, M., Abdolmohammadi‐Vahid, S., Ghaebi, M., Dolati, S., Abbaspour‐Aghdam, S., Danaii, S., Berjis, K., Madadi-Javid, R., Nouri, Z., Siahmansouri, H., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105730 · Cited by 47
Potential of Anti-Cancer Activity of Secondary Metabolic Products from Marine Fungi
Noman, E. A., Al-shaibani, M. M., Bakhrebah, M. A., Almoheer, R., Al-Sahari, M., Al-Gheethi, A. A. S., Mohamed, R. M. S. R., Almulaiky, Y. Q., & Abdulaal, W. H. (2021) · Journal of Fungi · doi:10.3390/jof7060436 · Cited by 46
Review of Carrier-Free Self-Assembly of Anticancer Nanodrugs
Ji, H., Wang, W., Qiao, O., & Hao, X. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c03315 · Cited by 45
CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy
Zhao, Y., Zhang, T., Duan, S., Davies, N. M., & Forrest, M. L. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.02.015 · Cited by 45
Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Rival‐Tringali, A. L., Euvrard, S., Decullier, É., Claudy, A., Faure, M., & Kanitakis, J. (2009) · PubMed · Cited by 45
Mammalian Target of Rapamycin's Distinct Roles and Effectiveness in Promoting Compensatory Axonal Sprouting in the Injured CNS
Lee, D.-H., Luo, X., Yungher, B. J., Bray, E. R., Lee, J. K., & Park, K. K. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1935-14.2014 · Cited by 44
Role of autophagy during the replication and pathogenesis of common mosquito-borne flavi- and alphaviruses
Echavarría-Consuegra, L., Smit, J. M., & Reggiori, F. (2019) · Open Biology · doi:10.1098/rsob.190009 · Cited by 46
Effective depletion of pre-existing anti-AAV antibodies requires broad immune targeting
Velazquez, V. M., Meadows, A. S., Pineda, R. J., Camboni, M., McCarty, D. M., & Fu, H. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.01.003 · Cited by 43
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice
Saha, A., Blando, J. M., Tremmel, L., & DiGiovanni, J. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0014 · Cited by 43
Self-assembled amphiphilic-dextran nanomicelles for delivery of rapamycin
Shaki, H., Ganji, F., Kempen, P. J., Dolatshahi‐Pirouz, A., & Vasheghani‐Farahani, E. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.01.010 · Cited by 42
Koschei the immortal and anti-aging drugs
Blagosklonny, M. V. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.520 · Cited by 41
Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Slingluff, C. L., Petroni, G. R., Molhoek, K. R., Brautigan, D. L., Chianese‐Bullock, K. A., Shada, A. L., Smolkin, M. E., Olson, W. C., Gaucher, A., Chase, C. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3919 · Cited by 40
The regulation of skin homeostasis, repair and the pathogenesis of skin diseases by spatiotemporal activation of epidermal mTOR signaling
Wang, J., Cui, B., Chen, Z., & Ding, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.950973 · Cited by 40
Hypoxia-inducible factor-1α polymorphisms and TSC1/2 mutations are complementary in head and neck cancers
HEBERT, C. A., Norris, K., Parashar, P., Ord, R. A., Nikitakis, N. G., & Sauk, J. J. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-3 · Cited by 39
mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?
Boone, J., ten Kate, F. J. W., Offerhaus, G. J. A., van Diest, P. J., Rinkes, I. H. M. B., & van Hillegersberg, R. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.055772 · Cited by 37
Phospho-mTOR: A novel target in regulation of renal lipid metabolism abnormality of diabetes
Hao, J., Zhu, L., Fan, L., Liu, Q., Zhao, X. Y., Liu, S., Xing, L., Feng, X., & Duan, H. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.06.013 · Cited by 36
The Impact of New Immunological Therapeutic Strategies on Recurrent Miscarriage and Recurrent Implantation Failure
Parhizkar, F., Motavalli, R., Maleki, L. A., Parhizkar, Z., Pourakbari, R., Kafil, H. S., Danaii, S., & Yousefi, M. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.05.008 · Cited by 36
Perspectives of Targeting mTORC1–S6K1 in Cardiovascular Aging
Ming, X., Montani, J., & Yang, Z. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00005 · Cited by 36
Improvement of the antiproliferative effect of Rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes
Ghanbarzadeh, S., Arami, S., Pourmoazzen, Z., & Khorrami, A. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.12.024 · Cited by 35
Point mutations of protein kinases and individualised cancer therapy
Davies, M. A., Hennessy, B. T., & Mills, G. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.16.2243 · Cited by 34
Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival
Sang, A. X., Glass, M. C., Ivison, G. T., Qu, X., Rigdon, J., Esquivel, C. O., Krams, S. M., & Martinez, O. M. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15216 · Cited by 35
Long‐Term Outcome After Liver Transplantation
Lim, K. B., & Schiano, T. D. (2012) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.21302 · Cited by 34
Rapamycin as a Therapy of Choice After Renal Transplantation in a Patient With Tuberous Sclerosis Complex
Tarasewicz, A., Dębska-Ślizień, A. M., Konopa, J., Zdrojewski, Z., & Rutkowski, P. L. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.06.227 · Cited by 34
Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer
Malone, T., Schäfer, L., Simon, N., Heavey, S., Cuffe, S., Finn, S., Moore, G., & Gately, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107454 · Cited by 33
Dynamic modelling of the mTOR signalling network reveals complex emergent behaviours conferred by DEPTOR
Varusai, T., & Nguyen, L. K. (2018) · Scientific Reports · doi:10.1038/s41598-017-18400-z · Cited by 33
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
Hanly, E. K., Bednarczyk, R. B., Tuli, N. Y., Moscatello, A. L., Halicka, H. D., Li, J., Geliebter, J., Darżynkiewicz, Z., & Tiwari, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4052 · Cited by 33
Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma
Hui, I. C.-F., Tung, E. K. K., Sze, K. M., Ching, Y.-P., & Ng, I. O. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02117.x · Cited by 32
mTOR is out of control in polycystic kidney disease
Mostov, K. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601352103 · Cited by 32
Therapeutic approaches targeting aging and cellular senescence in Huntington's disease
Bhat, A. A., Moglad, E. H. O., Afzal, M., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Ali, H., Pant, K., Singh, T. G., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70053 · Cited by 32
Immunostimulatory activity of lifespan-extending agents
Pedro, J. M. B., & Senovilla, L. (2013) · Aging · doi:10.18632/aging.100619 · Cited by 31
Monitoring Antitumor Efficacy of Rapamycin in Kaposi Sarcoma
Paolo, S. D., Teutonico, A., Ranieri, E., Gesualdo, L., & Schena, P. F. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.11.037 · Cited by 31

Authors: Law, B. K.
Affiliations: University of Florida (US)
Corresponding author: Law, Brian K.
ORCID: Law, Brian K.
Venue: Critical Reviews in Oncology/Hematology
Publisher: Elsevier BV
Published: 2005-10
Volume: 56
Issue: 1
Pages: 47-60
ISSN: 1040-8428 (ISSN-L)
DOI: 10.1016/j.critrevonc.2004.09.009
OpenAlex: W2764507256
Cited by: 252
References: 256
Citations by year: 2026: 1 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 14 · 2021: 9 · 2020: 8 · 2019: 18 · 2018: 9 · 2017: 15 · 2016: 9 · 2015: 10 · 2014: 23 · 2013: 16 · 2012: 10
FWCI: 0.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Critical Reviews in Oncology/Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords: rapamycin, mTOR signaling, immunosuppression, anticancer activity, tumor angiogenesis, apoptosis, tumor cell proliferation, cyclosporine, organ transplantation, tumor suppression, PI3K/Akt signaling, TSC1/TSC2, PTEN, LKB1, eIF4E
MeSH terms: Animals, Antineoplastic Agents, Cell Cycle, Drug Synergism, Humans, Immunosuppressive Agents, Neoplasms, Neovascularization, Pathologic, Protein Kinases, Drug Design, Signal Transduction, Molecular Chaperones, Sirolimus, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rapamycin: An anti-cancer immunosuppressant?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks